|
Title
|
Meeting/Journal
|
Date
|
Phase 1 study of the HSP90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer  |
AACR-NCI-EORTC International Conference
|
Nov-2011 |
| Pharmacokinetics, anti-tumor activity and therapeutic index of Nampt inhibitor MPC-8640 in mice |
AACR-NCI-EORTC International Conference
|
Nov-2011 |
| Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naïve to treatment with bevacizumab. |
American Society of Clinical Oncology |
Jun-2011 |
| Activity of the cancer metabolism inhibitor MPC-9528 in xenograft models: Comparison of different dosing schedules. |
American Society of Clinical Oncology |
Jun-2011 |
| MPI-0485520, a Small Molecule Inhibitor of IKKε/TBK1 is Active In aMouse Collagen-Induced Arthritis Model |
EULAR Annual European Congress of Rheumatology |
May-2011 |
| Coadministration of nicotinic acid with the Nampt inhibitor MPC-9528 enhances anti-tumor activity in Naprt deficient cancer cells in culture and in xenografts |
AACR 102nd Annual Meeting |
Apr-2011 |
| The Nampt inhibitor MPC-9528 synergizes with DNA damaging agents |
AACR 102nd Annual Meeting |
Apr-2011 |
| Basal NAD levels and Nampt expression correlate with in vitro and in vivo sensitivity of tumor cell lines to the Nampt inhibitor MPC-9528 |
AACR 102nd Annual Meeting |
Apr-2011 |
| Administration of Nicotinic Acid Reduces or Prevents Adverse Effects of MPC-9528, A Potent and Selective Nampt Inhibitor |
AACR 102nd Annual Meeting |
Apr-2011 |
| The cancer metabolism inhibitor MPC-9528 induces tumor regression in xenograft models with multiple dosing schedules by causing rapid and sustained reduction in tumor NAD |
AACR 102nd Annual Meeting |
Apr-2011 |
| Evaluation of the Pharmacokinetics and Efficacy of a Novel Pro-Drug of the HSP90 Inhibitor,MPC-3100, Designed with Improved Solubility |
AACR 102nd Annual Meeting |
Apr-2011 |
| MPC-3100, a synthetic Hsp90 inhibitor, induces biomarker changes in vitro and in vivo |
AACR 102nd Annual Meeting |
Apr-2011 |
| Anti-tumor Activity of MPC-3100, a Synthetic Hsp90 Inhibitor, in Combination with Erlotinib and Sorafenib |
AACR 102nd Annual Meeting |
Apr-2011 |
| Comparative In Vitro and In Vivo Metabolism of MPC-3100, an Oral HSP90 Inhibitor, in Rat, Dog, Monkey and Human |
AACR 102nd Annual Meeting |
Apr-2011 |
Verubulin hydrochloride
view abstract |
Drugs of the Future |
Dec-2010 |
| Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer view abstract |
Molecular Cancer Therapeutics
|
Dec-2010 |
| Phase 2 study of Azixa (verubulin or MPC-6827) for the treatment of glioblastoma after bevacizumab failure |
2010 Society for Neuro-Oncology Scientific Meeting |
Nov-2010 |
| The Nampt inhibitor MPC-9528 and the PARP inhibitor olaparib synergize in killing a BRCA--deficient cancer cell line |
22nd EORTC-NCI-AACR Symposium |
Nov-2010 |
| Anti-Tumor Activity of MPC-9528, GMX1778, and APO866: Nampt Inhibitors of Three Structural Classes |
22nd EORTC-NCI-AACR Symposium |
Nov-2010 |
| Inhibition of Cytosolic Nucleic Acid Receptor Pathways Using the Small Molecule IKKepsilon/TBK1 Kinase Inhibitor |
74th ACR/ARHP Annual Meeting |
Nov-2010 |
| MPC-9528, a cancer metabolism inhibitor, demonstrates greater therapeutic index in a Naprt1 deficient cancer xenograft model with co-administration of nicotinic acid |
Cancer and Metabolism: Pathways to the Future Symposium |
Sep-2010 |
Chemical Proteomics Identifies Nampt as the Target of CB30865, An Orphan Cytotoxic Compound
view abstract |
Chemistry and Biology |
Jun-2010 |
| A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme |
ASCO |
Jun-2010 |
| Final report: MPC-6827 is safely combined with temozolomide for the treatment of patients with metastatic melanoma |
ASCO |
Jun-2010 |
Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring
view abstract |
Bioorg Med Chem Lett. |
Apr- 2010 |
| Anti-tumor Activity of MPC-3100, a Synthetic, Orally Bioavailable Hsp90 Inhibitor, in Animal Models. |
AACR |
Apr-2010 |
| Cellular and In Vivo Properties of MPI-0485520, a Novel and Potent Small Molecule Inhibitor of IKKe |
FASEB |
Apr-2010 |
| TTK Kinase Inhibitor Development through Chemical Proteomics |
FASEB |
Apr-2010 |
| Identifying the target of an orphan compound: CB30865 is a Nampt inhibitor |
AACR |
Apr-2010 |
| MPI-0486348: A novel inhibitor of nicotinamide phosphoribosyltransferase induces tumor regression in a preclinical model |
AACR |
Apr-2010 |
| Next Generation Orally Bioavailable HIV-1 Maturation Inhibitors |
ACS |
Mar-2010 |
| MPC-4326 (bevirimat dimeglumine) Drug-Drug Interaction Profile |
CROI |
Feb-2010 |
| Inhibition of TTK Activates the p53 Pathway |
AACR-NCI-EORTC |
Nov-2009 |
| MPC-6827 is safely combined with temozolomide for the treatment of patients with metastatic melanoma |
AACR-NCI-EORTC |
Nov-2009 |
| Pharmacokinetic and pharmacodynamic data for MPC-3100, a fully synthetic, orally bioavailable HSP90 inhibitor, in cancer patients |
AACR-NCI-EORTC |
Nov-2009
|
| Inhibition of TTK Promotes Chromosome Segregation Defects in a Manner Distinct from Inhibitors of Aurora or PLK Mitotic Kinases |
AACR Frontiers in Basic Cancer Research |
Oct-2009 |
MPC-6827: anti-tumor activity in an orthotopic brain model and in combination with bevacizumab
view presentation |
SNO |
Oct-2009 |
Efficacy, Safety and Pharmacokinetics of MPC-4326 (bevirimat dimeglumine) 200mg BID and 300mg BID Monotherapy Administered for 14 days in Subjects with HIV-1 Infection
view presentation |
ICAAC |
Sep-2009 |
| Pharmacokinetics and Safety of a Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV-1 Infection |
ICAAC |
Sep-2009 |
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat
download PDF |
J. Virology |
May-2009 |
Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration
view abstract |
J Med Chem |
Apr-2009 |
| Azixa, a Microtubule Destabilizing Agent, in Solid Tumors: Results of a Phase 1 Trial |
AACR-NCI-EORTC |
Apr-2009 |
| Characterization of an orally bioavailable homolog of MPC-6827 (MPI-443803) that maintains high brain penetration |
AACR |
Apr-2009 |
| A Novel Small Molecule Inhibitor of the Mitotic Kinase TTK with Anti- Tumor Activity in Pre-Clinical Models |
AACR |
Apr-2009 |
| Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055 |
CROI |
Feb-2009 |
| Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects |
CROI |
Feb-2009 |
| Susceptibility of Diverse HIV-1 Patient Isolates to the Maturation Inhibitor, Bevirimat (MPC-4326*), is Determined by Clade-Specific Polymorphisms in Gag CA-SP1 |
CROI |
Feb-2009 |
| MPC-3100: A non-natural product Hsp90 inhibitor with anti-tumor activity in preclinical models. |
AACR-NCI-EORTC |
Oct-2008 |
| HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457) |
XVII International HIV Drug Resistance Workshop |
Jun-2008 |
| Role of Gag Polymorphisms in HIV-1 Sensitivity to the Maturation Inhibitor Bevirimat |
XVII International HIV Drug Resistance Workshop |
Jun-2008 |
| MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps |
Cancer Research |
Jun-2007 |
| Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases |
ASCO |
Jun-2007 |
| Vascular Disruption Effects of MPC-6827 |
AACR |
Jun-2007 |
| The first in class maturation inhibitor, PA-457, is a potent inhibitor of HIV drug-resistant isolates and acts synergistically with approved HIV drugs in vitro |
CROI |
Feb-2006 |
| Pharmacokinetic/Pharmacodynamic Effects of PA-457 In HIV-infected Patients Following A Single Oral Dose |
IAS |
Jul-2005 |
| MPC-6827, A Small Molecule Inhibitor of Microtubule Formation with High Brain Penetration: Absorption, Distribution, Metabolism, Excretion, and Clinical Considerations |
AACR |
Apr-2005 |
| MPC-6827, A Small Molecule Inhibitor of Microtubule Formation; Pharmacokinetics in Nu/+ Mice, Sprague Dawley Rats and Beagle Dogs Following Intravenous Administration. |
AACR |
Apr-2005 |
| MPC-6827: A small molecule inhibitor of microtubule formation that is not a substrate for multi-drug resistance pumps |
AACR |
Apr-2005 |
| Antitumor Activity of MPC-6827 in Human Breast, Colon, Pancreatic, Ovarian and Mouse Melanoma Tumor Xenografts in Athymic Nude Mice |
AACR |
Mar-2004 |
PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing
download PDF |
PNAS |
Nov-2003 |
The Protein Network of HIV Budding
view abstract |
Cell |
Sep-2003 |
Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding
view abstract |
Cell |
Oct-2001 |
